This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 …

Intracranial Meningioma

~Estimated

~$10 – $6,250

RTOG Foundation, Inc.NCT06955169

Phase 2

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma t…

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation

~Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT02523014

Phase 3

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningiom…

Grade 2 MeningiomaIntracranial Meningioma

~Estimated

~$10 – $7,500

NRG OncologyNCT03180268